PulseAugur
EN
LIVE 14:48:53
中文(ZH) 迪安诊断:控股股东及其一致行动人拟合计减持不超3%公司股份

Dean Diagnostics controlling shareholder to reduce stake by up to 3%

Dean Diagnostics announced that its controlling shareholder, Chen Haibin, and his affiliate Hangzhou Dikong, plan to collectively reduce their stake in the company by no more than 3%. This reduction will be executed through methods such as centralized bidding and block trading. Separately, TCL Zhonghuan released its performance forecast, anticipating a net loss attributable to shareholders of 3 billion to 3.3 billion yuan for the first half of 2026, a reduction from the previous year's loss of 4.24 billion yuan. AI

RANK_REASON The item is a digest of unrelated news items, none of which are significant enough to warrant a higher tier.

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Dean Diagnostics controlling shareholder to reduce stake by up to 3%

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    DiAn Diagnostics: Controlling Shareholder and Concerted Parties Plan to Reduce Holdings by a Combined 3% of Company Shares

    36氪获悉,迪安诊断公告,公司控股股东、实际控制人陈海斌及其一致行动人杭州迪控拟以集中竞价、大宗交易方式合计减持公司股份不超过3%。